Gulfstream Daily Brief

Regulatory intelligence and policy · Issue 054

MHRA sets women’s health agenda, EMA opens veterinary consultations

Today’s updates span UK evidence policy, clinical trial resources, European veterinary guidance, and a confirmed FDA rule date.

By Scott Morvay, Founder November 16, 2026 Official sources linked

MHRA

MHRA publishes Women’s Health Programme for 2026 to 2030

The programme supports better evidence and regulation of medicines and medical devices to improve health outcomes for women.

Read the official source

MHRA

MHRA updates its clinical trials hub

The collection brings together the UK legal framework, regulatory requirements, and guidance for designing, applying for, conducting, modifying, closing, and maintaining compliance in medicines trials.

Read the official source

EMA

EMA opens consultation on medically important VeDDRA terms

A draft guideline on veterinary good pharmacovigilance practices and the list of medically important VeDDRA terms is open for consultation.

Read the official source

EMA

EMA consults on revised VICH GL49

Revision 2, covering validation of analytical methods used in veterinary residue depletion studies, is available as a draft for consultation.

Read the official source

FDA

FDA confirms effective date for Orange B listing revocation

FDA confirmed September 8, 2026, as the effective date of the final order repealing the regulation that allowed Orange B on frankfurter and sausage casings or surfaces.

Read the official source

Why this matters

Regulatory teams should note MHRA’s focus on evidence gaps affecting women and use the consolidated UK trial resources when navigating clinical trial requirements. The EMA consultations provide formal opportunities to comment on veterinary pharmacovigilance terminology and analytical method validation, while FDA’s notice confirms the implementation date of a completed rulemaking action.

Scott Morvay

Founder, Gulfstream Intelligence

This brief provides general regulatory news and educational information. It is not legal or regulatory advice.